New Delhi (NVI): SCHOTT KAISHA, a market leader in pharma-packaging, has announced an investment of Rs 105 crore ( approximately EUR 12 million) into its existing facilities to increase its vial production by 300 million pieces.
The Indo-German venture with the international technology group, SCHOTT AG, plans to complete this production ramp-up within a record time of 12 months. A long-term investment plan and consistent infrastructure growth over the years has helped the company expand its production capabilities quickly.
The announcement comes at a time when drug manufacturers around the world are undergoing COVID-19 vaccine trials. Such complex medications are stored in Type 1 glass vials, which are produced at SCHOTT KAISHA facilities in Gujarat and Daman.
SCHOTT KAISHA has been a pioneer in the Indian market to provide customisable solutions to leading pharmaceutical players all over the world. It has always given preference to a ‘quality by design’ approach, benchmark manufacturing and quality control processes using breakthrough inspection technology, combined with best-in-class components.
Over the last 3 years, the company had invested approximately Rs 434 crore and set up two new plants in Umarsadi, Gujarat and Baddi, Himachal Pradesh.
With the recently opened facility in Umarsadi, SCHOTT KAISHA was already manufacturing over 3 billion pieces of ampoules, vials, syringes, and cartridges annually. The company is providing vaccine vials to all the key vaccine developers in the country as well as manufacturers abroad.
Rishad Dadachanji, Director, SCHOTT KAISHA said, “Pharma companies all around the world are working relentlessly to find an effective vaccine for COVID-19. As a front-runner in the pharma packaging segment, we are committed to support the vaccine developers with the best packaging solutions.”
“We are closely working with all our clients to supply them with vials and syringes for their vaccine trials and are continuously assessing their requirements to stay ahead of the curve,” he further said.
With the looming demand surge for vaccine vials, the pharma industry relies on quality products for storing their complex drug formulations with minimal threat of contamination.
-CHK
